Herpes Simplex Virus Treatment Market By  Type (Herpes simplex virus-1 infection, Herpes simplex virus-2 infection), By  Drug type (Acyclovir, Valacyclovir, Famciclovir), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Herpes Simplex Virus Treatment Market

Herpes simplex virus (HSV) is a highly contagious virus that causes infections in humans. Herpes simplex virus is of two types HSV-1, which typically causes oral herpes, and HSV-2, which typically causes genital herpes. Both types of HSVs are transmitted through direct contact with infected individuals, usually via oral or genital secretions.  HSV infection is a highly contagious and can be transmitted through contact with infected skin, mucous membranes, or bodily fluids. Antiviral medications help to manage the symptoms and reduce the frequency of infection.

Key factors driving the growth of the Herpes simplex virus treatment market include increase in people affected with the herpes simplex virus, increase in awareness and education about the risks and consequences of HSV infections. Public health campaigns and educational initiatives have led to improvements in the diagnosis and treatment of HSV infections which supports the market growth. Moreover, governments and non-governmental organizations are taking initiatives to raise awareness about sexually transmitted infections (STIs), including herpes simplex virus. This increased awareness among population is expected to create a demand for effective treatments among patients. In addition, availability of a wide range of antiviral drugs to treat HSV infections including acyclovir, valacyclovir, and famciclovir. These drugs are available in both topical and oral formulations, and are used to treat both primary and recurrent HSV infections. Thus, rise in demand for these drugs drive the market growth.

Furthermore, government initiatives and policies to promote public health and increase access to healthcare also have a positive impact on the HSV treatment market. European countries have a well-established healthcare system, and they invest significantly in R&D of new treatments. This rise in healthcare expenditure is expected to boost the market for herpes simplex virus treatment.   

The market also offers growth opportunities to the key players in the market.  The increase in R&D activities for herpes simplex virus treatment is driving the growth of the market. For instance, UBP Greater China (Shanghai) Co., Ltd is conducting phase-ll clinical trial to evaluate the safety and efficacy of UB-621 in adults with recurrent genital herpes simplex virus-2 infection. Therefore, products under clinical evaluation are projected to provide lucrative opportunity for market growth. Many research organizations and pharmaceutical companies are investing in the development of novel treatment options for herpes simplex virus, which is expected to drive the market growth. Thus, rise in R&D activities for herpes simplex virus provides the lucrative opportunity to the market growth.

The herpes simplex virus treatment market is segmented into type, drug type, capacity, distribution channel and region. On the basis of type, the market is categorized into herpes simplex virus-1 infection, and herpes simplex virus-2 infection. On the basis of drug type, it is categorized into acyclovir, valacyclovir, famciclovir. On the basis of distribution channel, it is segmented into hospital pharmacies, drug store and retail pharmacies, Online providers Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled in the study include Abbott Laboratories, Amneal Pharmaceuticals LLC., Emcure Pharmaceuticals Limited, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc.  The players in the market have been actively engaged in the adoption strategy such as product approval to remain competitive and gain advantage over the competitors in the market. For instance, in November 2020, Amneal Pharmaceuticals, LLC announced that it has received the approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%, generic version of Zovirax for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.

Key Market Insights

By type, the herpes simplex virus-1 infection segment was the highest revenue contributor to the market and is estimated to reach $1,514.20 million by 2031, with a CAGR of 1.9%. However, the herpes simplex virus-2 infection segment is estimated to be the fastest-growing segment with a CAGR of 2.6% during the forecast period.

By drug type, the valacyclovir segment dominated the global market in 2021.

Based on distribution channel, the hospital pharmacies segment was the highest revenue contributor to the market with a CAGR of 1.5% during the forecast period. However, the online providers segment is estimated to be the fastest-growing segment during the forecast period.

Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 2.8% during the forecast period.

 

Overview

The herpes simplex virus treatment market size valued for $1,724.27 million in 2021 and is estimated to reach $2,126.91 million by 2031, exhibiting a CAGR of 2.1% from 2022 to 2031.  

Herpes simplex virus (HSV) is a common viral infection that affects many people worldwide. There are two types of herpes simplex virus including type 1 (HSV-1) and type 2 (HSV-2). HSV-1 is usually associated with oral herpes, causing cold sores or fever blisters around the mouth. This type of herpes also causes genital herpes if it is transmitted through oral sex. HSV-2 is the most common cause of genital herpes, but it also causes oral herpes if it is transmitted through genital-to-oral contact. HSV can spread through sexual contact and virus also be transmitted in other ways. Herpes simplex virus treatment includes antiviral medications, topical creams or ointments, and home remedies to manage symptoms. The use of antiviral drugs has shown promising results in treating the disease.  

The global herpes simplex virus treatment market is majorly driven by increase in the incidences of herpes viral infections. In addition, rise in R&D activities for herpes simplex virus and development of newer & advanced formulations, such as tablets and creams, are expected to fuel the market growth. For instance, AiCuris Anti-infective Cures AG is a German biopharmaceutical company that is developing a new antiviral drug (Pritelivir) for the treatment of HSV infections. This drug, Pritelivir, works by inhibiting the virus from replicating and has been shown to be effective in reducing viral shedding and the frequency of infections in clinical trials. Thus, rise in R&D activities for herpes simplex virus propels the market growth.  

In contrast, limited awareness about the diseases such as sexually transmitted infections (STIs) and herpes virus in underdeveloped countries impedes the growth of the market. However, there is an increase in awareness of herpes infections, with rise in number of people are getting tested and diagnosed. This leads to increase in the demand for effective treatments in developed countries.    

Moreover, development and approvals of drugs for herpes simplex virus and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to drive the market growth during the forecast period. For instance, in November 2020, Amneal Pharmaceuticals, LLC announced that it has received the approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%, a generic version of Zovirax for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.  

The herpes simplex virus treatment market is segmented into type, drug type, distribution channel, and region. By type, the market is categorized into herpes simplex virus-1 infection, and herpes simplex virus-2 infection. By drug type, the market is classified into acyclovir, valacyclovir, and famciclovir. By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  

Major key players that operate in the global herpes simplex virus treatment market are Abbott Laboratories, Amneal Pharmaceuticals LLC., Emcure Pharmaceuticals Limited, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the herpes simplex virus treatment market analysis from 2021 to 2031 to identify the prevailing herpes simplex virus treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the herpes simplex virus treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global herpes simplex virus treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Emcure Pharmaceuticals Limite

Scope of Herpes Simplex Virus Treatment Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in prevalence of herpes simplex virus (HSV) infection

3.4.1.2. Increase in awareness about herpes simplex virus

3.4.2. Restraints

3.4.2.1. Stigma associated with herpes simplex virus

3.4.3. Opportunities

3.4.3.1. Increase in R&D activities

3.4.3.2. High growth potential in developing economies

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Herpes simplex virus-1 infection

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Herpes simplex virus-2 infection

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Acyclovir

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Valacyclovir

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Famciclovir

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Drug store and retail pharmacies

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online providers

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by  Type

7.2.3. Market size and forecast, by  Drug type

7.2.4. Market size and forecast, by Distribution channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by  Type

7.2.5.1.3. Market size and forecast, by  Drug type

7.2.5.1.4. Market size and forecast, by Distribution channel

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by  Type

7.2.5.2.3. Market size and forecast, by  Drug type

7.2.5.2.4. Market size and forecast, by Distribution channel

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by  Type

7.2.5.3.3. Market size and forecast, by  Drug type

7.2.5.3.4. Market size and forecast, by Distribution channel

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by  Type

7.3.3. Market size and forecast, by  Drug type

7.3.4. Market size and forecast, by Distribution channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by  Type

7.3.5.1.3. Market size and forecast, by  Drug type

7.3.5.1.4. Market size and forecast, by Distribution channel

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by  Type

7.3.5.2.3. Market size and forecast, by  Drug type

7.3.5.2.4. Market size and forecast, by Distribution channel

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by  Type

7.3.5.3.3. Market size and forecast, by  Drug type

7.3.5.3.4. Market size and forecast, by Distribution channel

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by  Type

7.3.5.4.3. Market size and forecast, by  Drug type

7.3.5.4.4. Market size and forecast, by Distribution channel

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by  Type

7.3.5.5.3. Market size and forecast, by  Drug type

7.3.5.5.4. Market size and forecast, by Distribution channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by  Type

7.3.5.6.3. Market size and forecast, by  Drug type

7.3.5.6.4. Market size and forecast, by Distribution channel

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by  Type

7.4.3. Market size and forecast, by  Drug type

7.4.4. Market size and forecast, by Distribution channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by  Type

7.4.5.1.3. Market size and forecast, by  Drug type

7.4.5.1.4. Market size and forecast, by Distribution channel

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by  Type

7.4.5.2.3. Market size and forecast, by  Drug type

7.4.5.2.4. Market size and forecast, by Distribution channel

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by  Type

7.4.5.3.3. Market size and forecast, by  Drug type

7.4.5.3.4. Market size and forecast, by Distribution channel

7.4.5.4. Australia

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by  Type

7.4.5.4.3. Market size and forecast, by  Drug type

7.4.5.4.4. Market size and forecast, by Distribution channel

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by  Type

7.4.5.5.3. Market size and forecast, by  Drug type

7.4.5.5.4. Market size and forecast, by Distribution channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by  Type

7.4.5.6.3. Market size and forecast, by  Drug type

7.4.5.6.4. Market size and forecast, by Distribution channel

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by  Type

7.5.3. Market size and forecast, by  Drug type

7.5.4. Market size and forecast, by Distribution channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by  Type

7.5.5.1.3. Market size and forecast, by  Drug type

7.5.5.1.4. Market size and forecast, by Distribution channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by  Type

7.5.5.2.3. Market size and forecast, by  Drug type

7.5.5.2.4. Market size and forecast, by Distribution channel

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by  Type

7.5.5.3.3. Market size and forecast, by  Drug type

7.5.5.3.4. Market size and forecast, by Distribution channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by  Type

7.5.5.4.3. Market size and forecast, by  Drug type

7.5.5.4.4. Market size and forecast, by Distribution channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2021

9.1. Abbott Laboratories

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.2. GlaxoSmithKline plc

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. Glenmark Pharmaceuticals Limited

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.4. Pfizer Inc.

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. Teva Pharmaceutical Industries Ltd.

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.6. Viatris Inc.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.7. Novartis AG

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Fresenius SE and Co. KGaA

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Amneal Pharmaceuticals LLC

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.9.7. Key strategic moves and developments

9.10. Emcure Pharmaceuticals Limited

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 02. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-1 INFECTION, BY REGION, 2021-2031 ($MILLION)

TABLE 03. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-2 INFECTION, BY REGION, 2021-2031 ($MILLION)

TABLE 04. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 05. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ACYCLOVIR, BY REGION, 2021-2031 ($MILLION)

TABLE 06. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR VALACYCLOVIR, BY REGION, 2021-2031 ($MILLION)

TABLE 07. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR FAMCICLOVIR, BY REGION, 2021-2031 ($MILLION)

TABLE 08. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 09. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 10. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 11. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)

TABLE 12. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 13. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 14. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 15. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 16. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 17. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 18. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 19. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 20. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 21. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 22. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 23. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 24. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 25. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 26. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 27. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 28. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 29. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 30. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 31. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 32. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 33. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 34. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 35. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 36. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 37. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 38. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 39. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 40. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 41. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 42. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 43. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 44. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 45. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 46. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 47. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 48. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 49. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 50. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 51. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 52. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 53. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 54. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 55. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 56. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 57. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 58. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 59. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 60. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 61. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 62. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 63. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 64. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 65. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 66. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 67. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 68. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 70. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 71. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 72. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 73. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 74. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 75. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 76. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 77. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 78. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 79. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 80. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 81. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 82. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 83. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)

TABLE 84. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)

TABLE 85. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 86. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 87. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 88. ABBOTT LABORATORIES: PRODUCT SEGMENTS

TABLE 89. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 90. GLAXOSMITHKLINE PLC: KEY EXECUTIVES

TABLE 91. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 92. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS

TABLE 93. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 94. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES

TABLE 95. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT

TABLE 96. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS

TABLE 97. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO

TABLE 98. PFIZER INC.: KEY EXECUTIVES

TABLE 99. PFIZER INC.: COMPANY SNAPSHOT

TABLE 100. PFIZER INC.: PRODUCT SEGMENTS

TABLE 101. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES

TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS

TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 106. VIATRIS INC.: KEY EXECUTIVES

TABLE 107. VIATRIS INC.: COMPANY SNAPSHOT

TABLE 108. VIATRIS INC.: PRODUCT SEGMENTS

TABLE 109. VIATRIS INC.: PRODUCT PORTFOLIO

TABLE 110. NOVARTIS AG: KEY EXECUTIVES

TABLE 111. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 112. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 113. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 114. FRESENIUS SE AND CO. KGAA: KEY EXECUTIVES

TABLE 115. FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT

TABLE 116. FRESENIUS SE AND CO. KGAA: PRODUCT SEGMENTS

TABLE 117. FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO

TABLE 118. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES

TABLE 119. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT

TABLE 120. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS

TABLE 121. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO

TABLE 122. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES

TABLE 123. EMCURE PHARMACEUTICALS LIMITED: KEY EXECUTIVES

TABLE 124. EMCURE PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT

TABLE 125. EMCURE PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS

TABLE 126. EMCURE PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031

FIGURE 02. SEGMENTATION OF HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031

FIGURE 03. TOP INVESTMENT POCKETS IN HERPES SIMPLEX VIRUS TREATMENT MARKET (2022-2031)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE BARGAINING POWER OF BUYERS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. HIGH THREAT OF NEW ENTRANTS

FIGURE 08. MODERATE INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALHERPES SIMPLEX VIRUS TREATMENT MARKET

FIGURE 10. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-1 INFECTION, BY COUNTRY 2021-2031(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-2 INFECTION, BY COUNTRY 2021-2031(%)

FIGURE 13. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ACYCLOVIR, BY COUNTRY 2021-2031(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR VALACYCLOVIR, BY COUNTRY 2021-2031(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR FAMCICLOVIR, BY COUNTRY 2021-2031(%)

FIGURE 17. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)

FIGURE 21. HERPES SIMPLEX VIRUS TREATMENT MARKET BY REGION, 2021

FIGURE 22. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 23. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 24. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 25. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 26. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 27. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 28. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 29. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 30. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 31. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 32. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 33. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 34. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 35. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 36. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 37. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 38. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 39. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 40. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)

FIGURE 41. TOP WINNING STRATEGIES, BY YEAR

FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 45. COMPETITIVE DASHBOARD

FIGURE 46. COMPETITIVE HEATMAP: HERPES SIMPLEX VIRUS TREATMENT MARKET

FIGURE 47. TOP PLAYER POSITIONING, 2021

FIGURE 48. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)

FIGURE 49. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 50. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 51. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)

FIGURE 52. GLENMARK PHARMACEUTICALS LIMITED: NET SALES, 2019-2021 ($MILLION)

FIGURE 53. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 54. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 55. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 56. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 59. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)

FIGURE 60. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 61. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 62. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 63. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 64. FRESENIUS SE AND CO. KGAA: NET SALES, 2019-2021 ($MILLION)

FIGURE 65. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 66. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 67. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 68. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 69. EMCURE PHARMACEUTICALS LIMITED: NET REVENUE, 2018-2020 ($MILLION)

FIGURE 70. EMCURE PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2020 (%